Cartalax belongs to a family of short peptides developed primarily by Vladimir Khavinson and colleagues at the Saint Petersburg Institute of Bioregulation and Gerontology — the same research group behind Epitalon. The "Khavinson peptides" or "bioregulators" are a distinctive class: short sequences (typically 2-4 amino acids) that Khavinson's group proposes work by entering cells, binding to specific DNA sequences in the minor groove, and directly modulating gene expression in ageing cells. They are named and numbered (T-31, T-38, etc.) in the original Russian literature and often have trade names for supplement/research use.
Cartalax (AED — Alanine, Glutamic acid, Aspartic acid) is derived from the alpha-1 chain of type XI collagen — a structural protein found in cartilage and connective tissue. This sequence specificity gives Cartalax its proposed tissue selectivity: it is hypothesised to preferentially influence connective tissue cells — chondrocytes, fibroblasts, renal epithelial cells — because its sequence mirrors the tissue's own structural protein.
The evidence base is concentrated in Russian and Eastern European research institutions, primarily in cell culture models and limited animal studies. Almost none of this work has been independently replicated by Western institutions, and no randomised controlled trials in humans have been published. This geographic and methodological concentration is a significant limitation when evaluating the literature.
The Khavinson Literature Context: The Khavinson peptide research programme is extensive but operates in an unusual scientific context. Studies are primarily from one research group in St. Petersburg, using methodologies not always published in peer-reviewed Western journals, and the claims are extraordinarily broad for three-amino-acid compounds. This does not mean the research is invalid — Epitalon's data, for instance, has some independent support — but it warrants healthy scepticism about effect sizes and replication. Cartalax specifically has the thinnest evidence of any Khavinson peptide in current community use.
The proposed mechanism for Cartalax is structurally different from every other peptide in this book. Rather than binding cell surface receptors and triggering signalling cascades, Khavinson's group proposes that Cartalax enters cells directly and binds to specific DNA sequences in the minor groove — physically interacting with the genome to modulate gene transcription in ageing cells.
The gene expression changes reported are dramatic: 1.6-fold to 5.6-fold shifts in IGF1, FOXO1, TERT, TNKS2, and NF-κB — "resetting aging cells to a more youthful expression pattern" according to the authors. The Saint Petersburg Institute also reported a 22% increase in TERT expression in chondrocytes and 28% higher proteoglycan content in cartilage from aged rats after 60 days of treatment. These are impressive numbers — in cell cultures and one rodent study, from one research group, not independently replicated.
Cartalax's community is small and concentrated among people exploring the full Khavinson peptide suite — typically alongside Epitalon, and sometimes Thymalfasin. It is not a mainstream peptide even by biohacking standards. Users tend to be specifically interested in connective tissue and joint health as part of a broader longevity protocol, attracted by the cartilage-specific angle and the senescence marker modulation claims.
Cartalax regulates chondrocyte gene expression to support cartilage matrix production. Its synergies provide the raw materials and complementary signals that chondrocytes need to execute the programme Cartalax is activating.
Disclaimer: These recommendations are educational and based on the known mechanisms of each compound. Individual responses vary. Consult a qualified healthcare provider before changing your supplement or exercise regimen, particularly when using experimental peptides.
The compounds and practices below have evidence supporting synergy with this peptide — either working on the same biological pathway, providing essential co-factors, or creating the physiological conditions that amplify the peptide's effects. Evidence ratings reflect the strength of the supporting science.
Cartalax sits at the most speculative end of the evidence spectrum in this book. The mechanism is genuinely interesting — direct DNA binding is an unusual proposal for a tripeptide, the SIRT6 upregulation target is one of the most credible longevity targets in geroscience, and the type XI collagen sequence specificity gives a logical tissue-targeting rationale. The cell culture data shows the expected molecular changes.
The problem is everything after the cell cultures. No independent replication. No animal studies outside the Russian literature. No human pharmacokinetic data. No safety trials. No clinical endpoints in humans. The research is concentrated in one institution that has a financial interest in the compounds it researches. The dramatic gene expression claims have not been verified by independent groups using independent methodology.
This does not mean Cartalax is useless — it means the evidence is too thin to make any confident claims about its effects in living humans. The p53 reduction angle adds a theoretical cancer concern that distinguishes it from most senolytic or anti-senescence approaches. People choosing to include Cartalax in a longevity protocol are making a very speculative bet on cell culture data from a single research group. That may or may not pay off — but calling it anything other than highly speculative would misrepresent what the evidence actually shows.